Table 1 Demographic and clinical data.

From: Intense exercise increases dopamine transporter and neuromelanin concentrations in the substantia nigra in Parkinson’s disease

 

Pre-exercise

Post-exercise

Age (years)

64.2 ± 5.2

Sex

6 males, 4 females

Disease duration (years)

2.0 ± 0.8

Symptom onset side

5 right, 5 left

Pre-exercise moderate-intensity exercise (hr/wk)

8.4 ± 4.8

Pre-exercise moderate-intensity MET/kg/wk

32.3 ± 20.3

Weight (kg)

76.6 ± 14.5

74.6 ± 14.1

H & Y

2.0 ± 0.0

2.0 ± 0.0

MDS-UPDRS I

8.6 ± 6.1

6.5 ± 4.2

MDS-UPDRS II

3.5 ± 2.2

3.1 ± 1.6

MDS-UPDRS III

27.6 ± 4.4

27.0 ± 8.4

MDS-UPDRS IV

1.0 ± 1.2

0.6 ± 1.0

MDS-UPDRS total

37.6 ± 13.6

37.2 ± 11.0

MoCA

28.1 ± 1.8

28.2 ± 1.1

STAI-T

34.5 ± 11.4

34.5 ± 12.4

BDI-II

7.8 ± 6.6

5.7 ± 5.0

Apathy

10.9 ± 6.8

8.2 ± 5.4

PDQ-39-SI

11.8 ± 7.0

9.2 ± 4.6

PFS-16

2.1 ± 1.2

2.0 ± 1.1

LEDD (mg)

245.0 ± 157.1

215.0 ± 173.3

  1. BDI-II Beck Depression Inventory-II, H & Y Hoehn & Yahr disease stage, LEDD Levodopa-equivalent daily dose, MDS-UPDRS Movement Disorders Society-Unified Parkinson’s Disease Rating Scale (I/II: Nonmotor/motor aspects of experiences of daily living, III: Motor examination, IV: Motor complications), MoCA Montreal Cognitive Assessment test, PDQ-39-SI The Parkinson’s Disease Questionnaire-39-Summary Index, PFS-16 Parkinson’s Fatigue Scale-16, STAI-T Spielberger Anxiety Inventory-Trait.
Back to article page